The company saw revenue decline and net losses rise in the second quarter.
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.95% and 36.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...
Investors liked what they heard in its Q4 update.
Morning Markets March S&P 500 futures (ESM2 3) this morning are up +0.79%, and March Nasdaq 100 E-Mini futures (NQM2 3) are up +0.82%. U.S. stock index futures this morning are moderately higher. Technology...
June S&P 500 futures (ESM23) are up +0.91%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.93% this morning after three major U.S. benchmark indices finished the regular session lower, while U.S....
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...